LY4178256

LY4178256 is a small molecule inhibitor of interleukin-17A (IL-17A) currently in early-stage clinical development by Eli Lilly and Company. It is designed as an oral therapeutic for the treatment of autoimmune and inflammatory diseases, aiming to provide a more convenient alternative to existing injectable biologics that target the IL-17 pathway. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants. By inhibiting IL-17A, LY4178256 blocks the pro-inflammatory signaling cascades that contribute to the pathogenesis of conditions such as psoriasis and psoriatic arthritis.